Tisotumab vedotin治疗晚期或转移性实体瘤患者(InnovaTV 201):一项首次人体、多中心、1-2期试验
这项首次人体1-2期研究在21个中心纳入晚期或转移性实体瘤患者,剂量递增阶段确定2.0 mg/kg每3周一次为推荐2期剂量,剂量扩展阶段147例患者中确认客观缓解率为15.6%(95%CI 10.2-22.5),安全性总体可控。
要点
- 2.0 mg/kg每3周一次为推荐2期剂量,剂量限制性毒性见于2.2 mg/kg。
- 剂量扩展阶段147例患者确认客观缓解率为15.6%(95%CI 10.2-22.5)。
- 最常见治疗中出现的不良事件为鼻出血(69%)、乏力(56%)和恶心(52%)。
核心结论
- Tisotumab vedotin在经重度治疗的多种实体瘤患者中安全性可控,并显示出令人鼓舞的初步抗肿瘤活性。
- 作者认为值得在实体瘤中继续评估tisotumab vedotin。
研究设计与样本
- InnovaTV 201为1-2期、开放标签、剂量递增和剂量扩展研究,在美国和欧洲21个中心开展。
- 剂量递增阶段纳入27例合格患者,采用传统3+3设计,tisotumab vedotin 0.3至2.2 mg/kg静脉给药每3周一次。
- 剂量扩展阶段纳入147例合格患者,按推荐2期剂量治疗。
- 纳入患者为卵巢癌、宫颈癌、子宫内膜癌、膀胱癌、前列腺癌、食管癌、头颈部鳞状细胞癌或非小细胞肺癌的复发、晚期或转移性癌症,ECOG体能状态0-1,且标准治疗复发后或不适合接受现有标准治疗。
- 主要终点为不良事件发生率,包括严重不良事件、输注相关、治疗相关、3级或更严重不良事件及研究药物相关不良事件,在至少接受一剂tisotumab vedotin的全部患者中分析。
主要发现
- 剂量限制性毒性包括3级2型糖尿病、黏膜炎和中性粒细胞减少性发热,见于2.2 mg/kg剂量;因此确定2.0 mg/kg静脉给药每3周一次为推荐2期剂量。
- 剂量扩展阶段最常见的(≥20%患者)任何级别治疗中出现的不良事件为鼻出血102/147例(69%)、乏力82/147例(56%)、恶心77/147例(52%)、脱发64/147例(44%)、结膜炎63/147例(43%)、食欲下降53/147例(36%)、便秘52/147例(35%)、腹泻44/147例(30%)、呕吐42/147例(29%)、周围神经病33/147例(22%)、干眼32/147例(22%)和腹痛30/147例(20%)。
- 最常见的3级或更严重不良事件为乏力14/147例(10%)、贫血8/147例(5%)、腹痛6/147例(4%)、低钾血症6/147例(4%)、结膜炎5/147例(3%)、低钠血症5/147例(3%)和呕吐5/147例(3%)。
- 147例患者中67例(46%)发生治疗中出现的严重不良事件,39/147例(27%)发生与研究药物相关的治疗中出现的严重不良事件。
- 147例患者中17例(12%)发生输注相关反应;跨瘤种确认的客观缓解比例为15.6%(95%CI 10.2-22.5;147例中23例)。
关键数值与推荐
- 推荐2期剂量为tisotumab vedotin 2.0 mg/kg静脉给药每3周一次。
- 剂量扩展阶段确认的客观缓解率为15.6%(95%CI 10.2-22.5;147例中23例)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. METHODS: InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0-1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. FINDINGS: Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2-22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. INTERPRETATIONS: Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. FUNDING: Genmab A/S.
引用
- de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019. PMID: 30745090. doi:10.1016/S1470-2045(18)30859-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。